GoAI
Get started
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$65.71

+$1.25 · +1.94%

Aug 21, 4:00 PM ET

TVTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

78

Undervalued

Momentum

62

Gaining

Sentiment

58

Mixed

Risk resilience

63

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Eric Dube
Listed since
Nov 8, 2012
Employees
497

Market position

Day range

Current $65.71

52-week range

Current $65.71

Open
$64.78
Previous close
$64.46
Volume
1.62M
0.79× average
Average volume
2.05M
Average daily volume
Market cap
6.11B USD
Beta
1.04
Market reference 1
50-day average
$57.8968
+13.50% above average
200-day average
$40.8206
+60.97% above average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends137%-19%-175%-331%Gross margin, FY2021: 97.10%Gross margin, FY2022: 95.96%Gross margin, FY2023: 92.12%Gross margin, FY2024: 96.68%Gross margin, FY2025: 97.89%Operating margin, FY2021: -151.27%Operating margin, FY2022: -292.17%Operating margin, FY2023: -267.24%Operating margin, FY2024: -138.88%Operating margin, FY2025: -12.80%Net margin, FY2021: -136.60%Net margin, FY2022: -254.41%Net margin, FY2023: -76.70%Net margin, FY2024: -137.90%Net margin, FY2025: -5.21%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 97.10%. Gross margin FY2022 95.96%. Gross margin FY2023 92.12%. Gross margin FY2024 96.68%. Gross margin FY2025 97.89%. Operating margin FY2021 -151.27%. Operating margin FY2022 -292.17%. Operating margin FY2023 -267.24%. Operating margin FY2024 -138.88%. Operating margin FY2025 -12.80%. Net margin FY2021 -136.60%. Net margin FY2022 -254.41%. Net margin FY2023 -76.70%. Net margin FY2024 -137.90%. Net margin FY2025 -5.21%.

Income trends

Revenue

490.73M USD+110.45%

Operating income

−62.82M USD+80.60%

Net income

−25.55M USD+92.06%
Income trends across reported periods578.61M USD227.07M USD−124.48M USD−476.02M USDRevenue, FY2021: 131.84M USDRevenue, FY2022: 109.46M USDRevenue, FY2023: 145.24M USDRevenue, FY2024: 233.18M USDRevenue, FY2025: 490.73M USDOperating income, FY2021: −199.43M USDOperating income, FY2022: −319.81M USDOperating income, FY2023: −388.14M USDOperating income, FY2024: −323.83M USDOperating income, FY2025: −62.82M USDNet income, FY2021: −180.09M USDNet income, FY2022: −278.48M USDNet income, FY2023: −111.4M USDNet income, FY2024: −321.55M USDNet income, FY2025: −25.55M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 131.84M USD. Revenue FY2022 109.46M USD. Revenue FY2023 145.24M USD. Revenue FY2024 233.18M USD. Revenue FY2025 490.73M USD. Operating income FY2021 −199.43M USD. Operating income FY2022 −319.81M USD. Operating income FY2023 −388.14M USD. Operating income FY2024 −323.83M USD. Operating income FY2025 −62.82M USD. Net income FY2021 −180.09M USD. Net income FY2022 −278.48M USD. Net income FY2023 −111.4M USD. Net income FY2024 −321.55M USD. Net income FY2025 −25.55M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue490.73M USD233.18M USD145.24M USD109.46M USD131.84M USD
Cost of goods sold10.34M USD7.74M USD11.45M USD4.42M USD3.82M USD
Gross profit480.39M USD225.43M USD133.79M USD105.04M USD128.02M USD
Research and development206.01M USD282.7M USD244.99M USD227.33M USD201.16M USD
Selling, general, and administrative337.2M USD264.12M USD265.54M USD197.52M USD126.28M USD
Operating expenses543.21M USD549.26M USD521.93M USD424.85M USD327.44M USD
Interest income12.72M USD17.82M USD21.77M USD6.28M USD1.99M USD
Interest expense10.75M USD11.18M USD11.33M USD11.01M USD19.68M USD
Depreciation and amortization60.74M USD43.56M USD38.53M USD20.72M USD12.75M USD
Operating income−62.82M USD−323.83M USD−388.14M USD−319.81M USD−199.43M USD
Net income−25.55M USD−321.55M USD−111.4M USD−278.48M USD−180.09M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 5 misses, 2 met estimates
Average EPS surprise
-4.56%
11 comparable reports
Latest EPS result
-0.37
Estimate -0.13 · Miss by 174.79%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.36-0.03-0.42-0.81Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual -0.73, estimate -0.58, surprise -25.86%, Miss. Q2 2025, reported May 1, 2025: actual -0.47, estimate -0.55, surprise +14.55%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.14, estimate -0.28, surprise +50.00%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.28, estimate -0.31, surprise +190.32%, Beat. Q1 2026, reported Feb 19, 2026: actual 0.03, estimate 0.03, surprise 0.00%, Met estimate. Q2 2026, reported May 4, 2026: actual -0.39, estimate -0.3, surprise -30.00%, Miss. Q3 2026, reported Aug 4, 2026: actual -0.37, estimate -0.135, surprise -174.79%, Miss. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates205.02M157.53M110.04M62.55MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 74.79M USD, estimate 72.38M USD, surprise +3.33%, Beat. Q2 2025, reported May 1, 2025: actual 81.73M USD, estimate 88.8M USD, surprise -7.96%, Miss. Q3 2025, reported Aug 6, 2025: actual 114.45M USD, estimate 99.55M USD, surprise +14.97%, Beat. Q4 2025, reported Oct 30, 2025: actual 164.86M USD, estimate 146.98M USD, surprise +12.16%, Beat. Q1 2026, reported Feb 19, 2026: actual 129.69M USD, estimate 144.55M USD, surprise -10.28%, Miss. Q2 2026, reported May 4, 2026: actual 127.2M USD, estimate 136.23M USD, surprise -6.63%, Miss. Q3 2026, reported Aug 4, 2026: actual 169.58M USD, estimate 157.27M USD, surprise +7.83%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 195.2M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$65.80

0.14% upside
Past 12 months12-month forecastHigh $78.00Average $65.80Low $49.00

Rating distribution

18 ratings
Strong buy00%
Buy1583%
Hold317%
Sell00%
Strong sell00%

TVTX news

seekingalpha.com

Travere Therapeutics: Valuation Suggests A Buy

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity…

Read source
gurufocus.com

Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum

HONG KONG, Aug 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered

Read source
marketbeat.com

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline

Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline…

Read source
defenseworld.net

Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX

Bank of America Corp DE lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) by 27.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…

Read source
businesswire.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees,…

Read source
seekingalpha.com

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)

Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risks and valuation concerns. Filspari's Q2 net sales surged 96% YoY to $141M, but $3B+ peak sales guidance faces new…

Read source

Corporate actions

Corporate action history

Stock split

Effective Nov 2, 2012

1:9

Stock split

Effective Jul 2, 2009

1:100

TVTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TVTX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
165.33M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
146.79M
Weight
0.18%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
143.88M
Weight
1.26%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
59.88M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
53.46M
Weight
0.36%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
43.5M
Weight
0.41%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
28.67M
Weight
0.12%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
28.04M
Weight
0.16%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research TVTX

research.disclaimer